問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chiayi Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

更新時間：2023-09-19

沈建亨
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

沈建亨

List

17Cases

2008-06-01 - 2010-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2017-11-01 - 2027-12-31

Phase III

Active
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    Durvalumab/ Tremelimumab

Participate Sites
10Sites

Recruiting1Sites

Terminated9Sites

陳三奇
Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-06-01 - 2026-08-31

Phase III

Active
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

  • Condition/Disease

    Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

  • Test Drug

    Nivolumab

Participate Sites
12Sites

Recruiting1Sites

Terminated10Sites

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2019-11-01 - 2025-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2014-04-01 - 2017-01-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2011-02-28 - 2012-02-28

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2022-02-16 - 2026-12-31

Others

Active
A Randomized, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects With Genotype WWOX-GG, Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma

  • Test Drug

    ADI-PEG 20

Participate Sites
9Sites

Recruiting9Sites

2013-01-15 - 2016-12-31

Phase II

Study to evaluate safety, tolerability, pharmacokinetics, and antiviral activity of ritonavir-boosted danoprevir in combination with peginterferon alfa-2a plus ribavirin in treatment-naïve patients of asian origin who have chronic hepatitis c genotype 1 with or without COMPENSATED cirrhosis

  • Condition/Disease

    chronic Hepatitis C

  • Test Drug

    Danoprevir (DNV) plus ritonavir (RTV)

Participate Sites
6Sites

Terminated6Sites

2011-07-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2007-09-01 - 2011-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB